See more : Sensys Gatso Group AB (publ) (SGG.ST) Income Statement Analysis – Financial Results
Complete financial analysis of Akebia Therapeutics, Inc. (AKBA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Akebia Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Aditya Birla Money Limited (BIRLAMONEY.NS) Income Statement Analysis – Financial Results
- Marley Spoon AG (MMM.AX) Income Statement Analysis – Financial Results
- Lincoln National Corporation (LNC-PD) Income Statement Analysis – Financial Results
- Russel Metals Inc. (RUS.TO) Income Statement Analysis – Financial Results
- CVS Health Corporation (CVS) Income Statement Analysis – Financial Results
Akebia Therapeutics, Inc. (AKBA)
About Akebia Therapeutics, Inc.
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 194.62M | 292.60M | 213.58M | 295.31M | 335.00M | 207.74M | 177.98M | 1.54M | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 74.15M | 84.80M | 153.39M | 295.91M | 145.34M | 7.69M | 617.00K | 115.79M | 96.00K | 23.26M | 0.00 | 0.00 |
| Gross Profit | 120.47M | 207.81M | 60.18M | -601.00K | 189.67M | 200.06M | 177.37M | -114.25M | -96.00K | -23.26M | 0.00 | 0.00 |
| Gross Profit Ratio | 61.90% | 71.02% | 28.18% | -0.20% | 56.62% | 96.30% | 99.65% | -7,443.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 63.08M | 129.11M | 147.85M | 218.49M | 322.97M | 291.07M | 230.89M | 115.79M | 43.02M | 25.40M | 10.78M | 5.63M |
| General & Administrative | 0.00 | 141.87M | 177.65M | 157.36M | 152.98M | 87.13M | 27.01M | 22.21M | 18.50M | 12.54M | 5.15M | 2.89M |
| Selling & Marketing | 100.23M | -3.18M | 174.16M | 153.95M | 149.46M | 87.06M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 100.23M | 141.87M | 174.16M | 153.95M | 149.46M | 87.06M | 27.01M | 22.21M | 18.50M | 12.54M | 5.15M | 2.89M |
| Other Expenses | 3.42M | -12.54M | 3.49M | 3.41M | 3.53M | 6.24M | 204.00K | -188.00K | 287.00K | 700.00K | 1.05M | 1.97M |
| Operating Expenses | 166.73M | 270.99M | 325.50M | 375.84M | 475.95M | 378.20M | 257.90M | 138.00M | 61.51M | 37.94M | 15.93M | 8.52M |
| Cost & Expenses | 240.88M | 355.78M | 478.90M | 671.75M | 621.29M | 385.88M | 257.90M | 138.00M | 61.51M | 37.94M | 15.93M | 8.52M |
| Interest Income | 0.00 | 15.69M | 19.95M | 8.92M | 2.19M | 6.15M | 2.80M | 901.00K | 0.00 | 0.00 | 0.00 | 1.64M |
| Interest Expense | 6.03M | 15.69M | 19.94M | 8.87M | 1.40M | 6.15M | 0.00 | 0.00 | 510.00K | 206.00K | 703.57K | 0.00 |
| Depreciation & Amortization | 37.63M | 35.28M | 36.13M | 33.59M | 36.42M | 2.42M | 617.00K | 296.00K | 96.00K | 49.00K | 1.28K | 39.16K |
| EBITDA | -6.87M | -43.26M | -225.96M | -341.00M | -247.64M | -178.09M | -76.06M | -136.16M | -61.42M | -37.89M | -12.46M | -6.55M |
| EBITDA Ratio | -3.53% | -15.84% | -124.23% | -127.47% | -85.46% | -85.75% | -44.55% | -8,870.62% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -46.26M | -63.18M | -265.32M | -376.44M | -286.29M | -178.14M | -79.92M | -136.46M | -61.51M | -37.94M | -15.93M | -8.52M |
| Operating Income Ratio | -23.77% | -21.59% | -124.23% | -127.47% | -85.46% | -85.75% | -44.90% | -8,889.90% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -5.67M | -13.45M | -17.52M | -5.63M | -2.00K | 6.24M | 3.00M | 713.00K | 497.00K | 906.00K | 2.77M | 327.00K |
| Income Before Tax | -51.93M | -92.56M | -282.84M | -383.46M | -286.29M | -171.90M | -76.91M | -135.75M | -60.72M | -37.03M | -13.17M | -8.20M |
| Income Before Tax Ratio | -26.68% | -31.63% | -132.43% | -129.85% | -85.46% | -82.75% | -43.21% | -8,843.45% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 13.45M | -37.97M | -33.59M | -6.63M | -28.34M | -2.80M | -901.00K | -510.00K | -206.00K | 1.75M | 1.60M |
| Net Income | -51.93M | -106.01M | -244.87M | -349.87M | -279.66M | -171.90M | -76.91M | -135.75M | -60.72M | -37.03M | -13.17M | -8.20M |
| Net Income Ratio | -26.68% | -36.23% | -114.65% | -118.48% | -83.48% | -82.75% | -43.21% | -8,843.45% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.28 | -0.58 | -1.48 | -2.53 | -2.36 | -1.47 | -1.77 | -3.60 | -2.29 | -2.40 | -0.68 | -0.81 |
| EPS Diluted | -0.28 | -0.58 | -1.48 | -2.53 | -2.36 | -1.47 | -1.77 | -3.60 | -2.29 | -2.40 | -0.68 | -0.81 |
| Weighted Avg Shares Out | 187.47M | 182.78M | 165.95M | 138.46M | 118.40M | 116.89M | 43.50M | 37.72M | 26.47M | 15.41M | 19.27M | 10.13M |
| Weighted Avg Shares Out (Dil) | 187.47M | 182.78M | 165.95M | 138.46M | 118.40M | 116.89M | 43.50M | 37.72M | 26.47M | 15.41M | 19.27M | 10.13M |
New Strong Sell Stocks for December 5th
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
U.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo® (vadadustat) for CKD Patients on Dialysis
New Strong Sell Stocks for November 27th
Akebia Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference
New Strong Sell Stocks for November 22nd
Q3 2024 Earnings: Hold Akebia Therapeutics
Vadadustat Alternative Dosing Study Results Published in the American Journal of Kidney Disease
Akebia Therapeutics to Present at the Jefferies London Healthcare Conference
Akebia Therapeutics, Inc. (AKBA) Q3 2024 Earnings Call Transcript
Source: https://incomestatements.info
Category: Stock Reports